Monsenso enables personalised care beyond the pill and
value demonstration to payers by capturing patient data
across their care journey.
Monsenso’s digital companion solution accompanies new treatments, while complementing existing care pathways.
Our solution enables education about a new treatment, direct communication and data sharing to support the identification of treatment responders, high volume prescribers and outcomes to facilitate value-based agreements.
Our solution is a CE Class 1 medical device that captures ePRO, symptom and wearable device data to provide a holistic view of the patient journey.
Monsenso enables personalised support and patient data capture throughout the care journey.
Collect self-reported data and provide patients with tools to practice helpful skills in day-to-day life and promote medical adherence enabling them to better manage their condition between consultations.
Provide clinicians with insights into patients’ symptoms, adherence and outcomes to demonstrate the value of a treatment in a transparent way.
Demonstrate real-world value to regulators and payers to support coverage, differentiate from existing treatments,
value-based reimbursement and label expansion.
Monsenso’s digital companion solution complements existing therapies and care pathways by empowering patients to better understand and manage their mental health between clinical visits.
Monsenso enables direct communication and data sharing between all life sciences stakeholders, enabling a personalised medication and treatment approach and improving treatment adherence.
Monsenso is proud to offer expertise in a number of therapeutic areas within the mental health domain, supporting both daily clinical practice as well as clinical trials.
Extensive track record in global deployments within academia, healthcare, social care and pharmaceutical companies across a variety of mental health disorders.
A configurable, customisable cloud-based SaaS solution, that can be quickly configured to meet the needs of the target patient population and care pathway.
Monsenso adheres to the highest security standards. CE-marked, Class I Medical Device, as well as TGA and Cyber Essentials Certification. Monsenso A/S is certified in ISO 13485 and ISO 27001.
Our expert team is ready to demonstrate the Monsenso digital companion solution and to answer any questions you might have.
[1] Lubkeman, M., Lee, Myrto., and Barrios, G. (2020) What do Patients Want, and is Pharma Delivering? Boston Consulting Group
[2] Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009 Mar;70(3):344-53.
[3] Cohen, O., Fox, B., and Wright, P. (2020) COVID-19 and commercial pharma: Navigating and uneven recovery. McKinsey & Company
[4] Semahegn, A., Torpey, K., Manu, A. et al. (2020) Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Systems Reviews 9, 17
[5] American Medical Association: https://www.ama-assn.org/delivering-care/patient-support-advocacy/8-reasons-patients-dont-take-their-medications
Psychiatrist